Imagine living with heart failure, where every beat feels like a struggle. This condition, especially when your heart doesn’t pump effectively, can limit your daily life and overall health. The PRIME-HFrEF trial explored whether stem cells from umbilical cords could help. In this study, 40 patients received three infusions of these stem cells over six weeks. The goal was to see if this treatment was safe and if it could improve heart function. While the treatment was generally safe, some patients experienced higher levels of a substance related to blood clotting. Interestingly, those who received the stem cells showed better results in one area of heart function compared to those who didn't, but overall heart pumping ability didn’t improve as hoped. For patients, this means that while there’s potential for stem cells to help, we still need to understand the risks involved. It’s a step forward, but caution is necessary as researchers continue to explore how to make these treatments safer and more effective.
Could Stem Cells Offer New Hope for Heart Failure Patients?
Plain Language Summary
What this means for you:
Stem cell treatments for heart failure show promise but come with risks, reminding us that hope must be balanced with caution. What this means for you:
Stem cell treatments for heart failure show promise but come with risks, reminding us that hope must be balanced with caution. View Original Abstract ↓
The safety of multi-dose mesenchymal stem cell (MSC) regimens has seldom been systematically investigated. The PRIME-HFrEF (Prospective Randomized Controlled Study of Multiple Intravenous Infusions of Umbilical Cord-derived MSCs in Patients with Heart Failure and Reduced Ejection Fraction) trial was a single-center, randomized, placebo-controlled, investigator-initiated study (ClinicalTrials.gov identifier: NCT04992832) that enrolled 40 patients. The trial aimed to evaluate the safety of three intravenous infusions of Umbilical Cord-derived MSCs (UC-MSCs) administered at six-week intervals in patients with heart failure and reduced ejection fraction (HFrEF), while also collecting exploratory efficacy data. The primary safety endpoint was the incidence of serious adverse events (SAEs), and the primary efficacy endpoint was the change (Δ) in left ventricular ejection fraction (LVEF). Secondary efficacy endpoints included changes in right ventricular (RV) end-systolic and end-diastolic volumes (ESV and EDV). Thirty-nine patients completed 12 study visits over a 360-day follow-up period or until death. The incidence of SAEs did not differ significantly between treatment groups. However, UC-MSC-treated patients exhibited elevated D-dimer levels, suggesting a treatment-associated increase in coagulability. D-dimer levels were negatively correlated with LVEF, and no significant difference in ΔLVEF was observed between groups. In contrast, the improvement in ΔRVESV was significantly greater in the UC-MSC group than in placebo-treated patients (P = 0.033). In summary, multi-dose UC-MSC infusions were safely administered to patients with HFrEF and were associated with improvements in RV volumes. However, these benefits were accompanied by transient increases in coagulability, which may have attenuated potential improvements in left ventricular contractile function.